Puma Biotech Q1 net loss $3.8M; raises 2026 revenue and net income guidance on NERLYNX demand

PUMA BIOTECHNOLOGY, INC.

2026-Q1 EPS reported -$0.07 revenue$44,814,000

Q1 product revenue $42.0M vs $43.1M YoY; GAAP net loss $3.8M ($0.07/share) vs net income $3.0M.
Non-GAAP adjusted net loss $1.9M ($0.04/share) vs adjusted net income $5.0M ($0.10) YoY.
FY 2026 guidance raised: net product revenue $202-206M (prior $194-198M); net income $16-19M (prior $10-13M).
Debt fully repaid on May 4, 2026; cash & securities $101.5M at March 31, 2026, up from $97.5M.
Second-quarter Q2 2026 net product revenue guidance $50-52M, net income $2-4M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PUMA BIOTECHNOLOGY, INC. reported first quarter ended March 31, 2026 results: revenue $44.8 million, net income net loss of $3.8 million, EPS $0.07 per basic and diluted share. Guidance raised.

Period: first quarter ended March 31, 2026
Revenue: $44.8 million
Net income: net loss of $3.8 million
EPS: $0.07 per basic and diluted share
Guidance: raised
Result: reported results

Exact text from the filing

consists of product revenue, net from sales of NERLYNX, Puma’s first commercial product, and royalty revenue. For the first quarter ended March 31, 2026 , total revenue was $44.8 million, of which $42.0 million was net product revenue and $2.8 million was royalty revenue. This compares to total revenue of $46.0 million in the first quarter of 2025 , of which

View on SEC.gov

Browse all earnings releases →

PUMA BIOTECHNOLOGY, INC. filing history →

Source: SEC EDGAR

accession 0001437749-26-015621

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.